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Abstract
Dementia is a leading cause of death in the United States. This article outlines the current
understanding of advanced dementia and identifies research priorities for the next decade.
Research over the past 25 years has largely focused on describing the experience of patients with
advanced dementia. This work has delineated abundant opportunities for improvement, including
greater recognition of advanced dementia as a terminal illness, better treatment of distressing
symptoms, increased access to hospice and palliative care services, and less use of costly and
aggressive treatments that may be of limited clinical benefit. Addressing those opportunities must
be the overarching objective for the field in the coming decade. Priority areas include designing
and testing interventions that promote high-quality, goal-directed care; health policy research to
identify strategies that incentivize cost-effective and evidence-based care; implementation studies
of promising interventions and policies; and further development of disease-specific outcome
measures. There is great need and opportunity to improve outcomes, contain expenditures, reduce
disparities, and better coordinate care for the millions of persons in the United States who have
advanced dementia.
More than 5 million Americans have Alzheimer disease, and this number is expected to
reach 13 million by 2050 (1) (Figure 1). In 2009, Alzheimer disease was the sixth-leading
cause of death in the United States, a ranking that has steadily risen during the past decade
(2). Aggregate health care expenditures for dementia are projected to exceed $183 billion in
2011 and reach $1.1 trillion by 2050 (3). Expenditures are highest in late-stage disease,
largely because of Medicaid spending for care at nursing homes (4), where approximately
70% of these patients die (5). Altogether, the societal burden of advanced dementia is
substantial and increasing.
Advanced dementia has been relatively underrecognized as a terminal illness (6–8).
Initiatives aimed at improving the experience of patients dying of this disease have lagged
behind those of more commonly recognized life-threatening conditions, such as cancer.
Advanced dementia emerged as a topic in the scientific literature approximately 25 years
ago (9). Since then, research devoted to this field has increased (10). The objectives of this
article are to outline our current understanding of advanced dementia and, with that
foundation, identify the most pressing research priorities for the next decade.
Current Understanding of Advanced Dementia
Clinical Course
The last year of life in persons with advanced dementia differs from that of persons with
other common causes of death, in that it is characterized by a prolonged trajectory of severe
disability (11). The Global Deterioration Scale (12) is a validated and reliable instrument
that describes the clinical progression of dementia (Table 1). The scale ranges from stages 1
to 7, with higher scores indicating more severe dementia.
Stage 7 of the Global Deterioration Scale provides a useful description of the features of
advanced dementia for clinical and research purposes: profound memory deficits (inability
to recognize family members), speech limited to fewer than 5 words, total functional
dependence, incontinence, and inability to ambulate. The CASCADE (Choices, Attitudes,
and Strategies for Care of Advanced Dementia at the End-of-Life) study used this definition
to describe the clinical course of 323 nursing home residents with advanced dementia (13).
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Over 18 months, 55% of the cohort died, 41% had pneumonia, 51% had a febrile episode,
and 86% developed an eating problem. Other major acute illnesses (for example, hip
fracture and myocardial infarction) were rare.
The CASCADE study thus confirmed that advanced dementia is characterized by a high
mortality rate and the onset of infectious episodes and eating problems. Moreover, it
demonstrated that most patients with advanced dementia die of this disease and its expected
complications, not other acute illnesses.
Prognosis
Prognostication has important implications for clinical decision making and for accessing
Medicare hospice benefits, which requires an estimated survival time of less than 6 months
(13–15). The development of risk models for mortality that accurately estimate survival in
advanced dementia has unfortunately proved elusive (16–21). In a prospective validation
study (16), the 12-item Advanced Dementia Prognostic Tool predicted 6-month survival
with only modest accuracy (area under the receiver-operating characteristic curve, 0.67);
however, these findings were better than those of current Medicare hospice eligibility
guidelines (area under the receiver-operating characteristic curve, 0.55) (16). The difficulty
of estimating 6-month survival in advanced dementia suggests that access to palliative care
for these patients should be guided not by their prognosis but rather by their preference to
focus care on maximizing comfort and quality of life.
Sources of Distress
Patients with advanced dementia commonly experience distressing symptoms that are
amenable to treatment (6, 13, 22–29). In the CASCADE study, the proportion of nursing
home residents with advanced dementia who experienced pain and dyspnea increased as
death approached, in a pattern similar to that of patients with cancer who are dying (30).
Assessing patients’ symptom distress is difficult because of their loss of language skills, but
advanced dementia-specific instruments have been developed that quantify symptoms on the
basis of the observations of caregivers. Several measures have gained greater endorsement
because of their favorable psychometric properties and increasing collective experience
among investigators (31–34).
Management of Common Complications
Treatment decisions in advanced dementia should be guided by patients’ care preferences as
specified in advance directives or as perceived by their proxies. Goals of care must be used
to guide initiation of new treatments, as well as the withdrawal of ongoing treatments. Most
proxies state that comfort is the primary goal of care (13, 35), although patients with
advanced dementia commonly receive treatments that are inconsistent with this goal (36–
43). Possible reasons underlying this disconnect include such factors as inadequate advance
care planning (40, 43, 44), the challenges of prognostication (16–21), providers giving
misinformed and inconsistent counseling to proxies (13, 45), cultural influences (43, 46–48),
limited access to high-quality palliative care that is tailored to the unique needs of patients
with dementia (7, 39), and misaligned fiscal incentives in a fee-for-service health care
system (49, 50).
Treatment choices regarding eating problems and infections are the most common decisions
that proxies confront (51). A substantial body of research exists on managing feeding
problems in advanced dementia (41, 44, 52–60). This topic has served as the paradigm for
approaching dementia as a terminal illness with respect to examination of outcomes,
decision making, and health care utilization.
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Treatment options for feeding problems include continued assisted oral feeding (when
possible) or tube feeding. In the United States, approximately one third of nursing home
residents with advanced dementia who develop feeding problems are tube-fed (40).
However, observational studies have consistently failed to demonstrate any clinical benefits
of this intervention in this population (41, 44, 53). This evidence, together with an
appreciation of eating problems as part of the natural history of advanced dementia, has led
experts to advocate against the use of tube feeding in this condition (53, 55, 61).
Decision making for infections involves whether to administer antimicrobials or to use
supportive measures only. Antimicrobial use is extensive in advanced dementia (62–66) and
increases as death approaches (66). Up to 40% of patients with advanced dementia receive
antimicrobials in the last 2 weeks of life (66). The extent to which antimicrobials
meaningfully extend life or improve comfort in these patients, for whom infections are often
a terminal event, remains unclear (38, 65, 67–69). Nursing home residents with advanced
dementia are 3 times more likely than other residents to be colonized with antimicrobial-
resistant bacteria (70). Altogether, the widespread use of antimicrobials in advanced
dementia raises concerns not only from the perspective of individual benefits and burdens
near the end of life but also from a public health standpoint with respect to the emergence of
antimicrobial-resistant bacteria.
Health Care Utilization
Approximately 16% of persons in the United States who die of dementia do so in hospitals
(5). Nursing home residents with advanced dementia experience an average of 1.6 hospital
transfers in the last 90 days of life (42), and residents living in regions with higher transfer
rates experience worse end-of-life outcomes (43). Hospitalizations can be traumatic for
these frail patients (37), as they receive care from unfamiliar providers and undergo
uncomfortable tests and interventions (36, 38, 42, 42).
In the CASCADE study, hospitalizations accounted for 30% of Medicare expenditures; care
at skilled nursing facilities after hospitalization accounted for an additional 10% (50).
Research suggests that most conditions precipitating hospitalization in advanced dementia
(for example, pneumonia) can be treated with the same efficacy in the community or nursing
home setting (64, 65, 71, 72). For most patients for whom comfort is the priority (13, 35),
hospitalization is seldom consistent with this goal, albeit with rare exceptions (for example,
a hip fracture).
Hospice care is a beneficial (26, 73–75) yet under-utilized service in advanced dementia (7).
Patients dying with dementia who received hospice care have better symptom management
(26, 74), fewer terminal hospitalizations (76), and greater family satisfaction with care than
those not receiving hospice care (28, 74). Trends indicate that hospice enrollment of patients
with dementia is increasing; however, only 11% of hospice recipients in 2009 were reported
to have a primary diagnosis of dementia, whereas 40% had cancer (77). Hospice
professionals cite prognostication as the main hindrance to enrolling patients with dementia
(78).
There are profound disparities in advanced dementia care. Nonwhite race is the most
consistent risk factor associated with outcomes considered markers of poor-quality end-of-
life care, including increased use of tube feeding (40), terminal hospitalizations (43), and
lack of advance directives (46, 47). However, even after patient characteristics are controlled
for, these outcomes vary dramatically across the United States in a strikingly consistent
pattern, with a general propensity for worse quality of care in the southeast (42, 43, 48, 52,
54, 58, 79). The reasons for these disparities remain unclear, but they underscore that care of
advanced dementia care is driven by a complex interplay of individual preferences, cultural
Mitchell et al. Page 4













influences, regional market factors, facility characteristics, local practice patterns, and health
care policies.
Strategies to Improve Care
Our understanding of successful strategies to improve care in advanced dementia is largely
based on observational data. Modifiable factors most consistently shown to be associated
with better palliative care outcomes for patients with advanced dementia in cohort studies
include the presence of advance directives (for example, do-not-hospitalize orders) (40, 43–
45, 50), better counseling of patients’ health care proxies (13, 45), residence in a special care
dementia unit (45, 51), use of hospice (26, 28, 74, 76, 80), and the presence of nurse
practitioners on-site in a nursing home (40, 47).
There are few randomized, controlled trials (RCTs) of interventions in advanced dementia,
of which only 2 had adequate methodological rigor to warrant comment (56, 81). Both
studies evaluated decision support tools. In one study, healthy elderly persons who were
randomly assigned to watch a video showing a patient with advanced dementia were more
likely to prefer comfort care (vs. life prolongation) than were persons who were randomly
assigned to listen to a verbal description of advanced dementia (81). The second study was a
cluster RCT in 24 nursing homes of a decision aid to help proxies of residents with
advanced dementia make treatment decisions for feeding problems (56). Proxies in the
intervention facilities (vs. the control facilities) had reduced decisional conflict, increased
knowledge, and better communication with providers about feeding decisions.
Research Priorities
To date, research has largely focused on describing the experience of patients with advanced
dementia and the care they receive. This work has delineated abundant opportunities for
improvement. Addressing those opportunities must be the overarching objective for
advanced dementia research in the coming decade. Table 2 shows the research priorities
needed to achieve that objective, categorized by discipline; lists specific goals within each
discipline; and provides examples of research initiatives for each goal.
Designing and testing interventions that promote high-quality, goal-directed care across
health care settings will be a cornerstone for future research in advanced dementia. An
example of such a study would be an RCT of an intervention to avoid unwanted
hospitalizations of nursing home residents with advanced dementia whose goals of care are
primarily comfort. Interventions that reduce disparities in the quality of care provided to
patients with advanced dementia who are of various ethnic and racial backgrounds are also
needed. Clinical trials in advanced dementia, while essential, will not be straightforward to
conduct; interventions are often complex, settings are not well-suited to research (for
example, nursing homes), and outcomes are challenging to define and measure. Nonetheless,
the success of prior RCTs that faced similar challenges demonstrates that these hurdles can
be overcome (56, 71, 81, 82).
Health policy research is essential to move advanced dementia care forward. A primary goal
of this research should be to identify policies that incentivize cost-effective and evidence-
based care without comprising the quality of palliative care provided to these vulnerable
patients (49). Expanding access to the Medicare hospice benefit and broad-based palliative
care programs is a key part of the equation. For example, prior work clearly shows that the
6-month hospice eligibility guidelines are problematic (16). Thus, research that explores
novel approaches to enroll dementia patients into hospice is warranted. Comparative
effectiveness research that evaluates different strategies to treat common complications
(such as pneumonia) would also inform policy.
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The anticipated complexity of clinical interventions and policies to improve advanced
dementia care necessitate the inclusion of implementation science as a key priority to ensure
that they can be effectively translated into practice. The Patient Protection and Affordable
Care Act presents a timely opportunity for demonstration projects that evaluate alternative
financial structures to reduce unwarranted and unwanted hospitalizations for nursing home
residents with advanced dementia, such as bundled payments or capitated programs, similar
to the Program of All Inclusive Care for the Elderly (which integrates Medicare and
Medicaid financing for frail elderly patients) (49).
Although progress has been made in outcomes measurement, many gaps remain. For
example, there is no measure to quantify the stress that families of nursing home residents
with advanced dementia experience. A disease-specific utility-based measure that takes into
account health-related quality of life must be developed to conduct comparative and cost
effectiveness research. Finally, greater delineation of meaningful effect sizes of existing
measures is necessary to plan trials that will use these instruments as outcomes (31–34).
The research priorities set forth in this report align with those of the National Alzheimer’s
Project Act, which was signed into law in January 2011. This projects calls for the
expansion and coordination of research and health services delivery across federal agencies
for Alzheimer disease and related dementias in order to achieve 2 top priorities: improve the
health outcomes of patients with dementia and reduce the financial burden of the disease at
an individual and societal level. The act further prioritizes the need to reduce disparities and
improve the coordination of dementia care, and it stresses the need for initiatives aimed at
prevention and early detection of dementia. However, if the top priorities of the act are to be
met, significant focus must be placed on the millions of persons in the United States in the
advanced stage of the disease, for whom there is great need and opportunity to improve
patient outcomes, contain health care expenditures, reduce disparities, and better coordinate
care.
Accomplishing these priorities will depend on several factors, including research funding.
To date, roughly 63% of advanced dementia research has been supported by grants from the
National Institutes of Health. However, with the National Institutes of Health budget at
unprecedented lows, greater support from other federal agencies and philanthropic sources
will be critical. In addition, the number of senior researchers dedicated to this field is small.
Ongoing work will require close collaboration and intellectual and financial investment into
the training of young investigators. Dissemination of key research findings through the
education of policy-makers, health care providers, and the public will be an essential step in
translating this work into better advanced dementia care. Finally, the millions of Americans
with dementia and their families are perhaps the most important stakeholders in this
research. Ultimately, their advocacy and enfranchisement may play the greatest role in
driving advanced dementia research forward through the next decade.
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Table 1
Stages of Dementia Described by the Global Deterioration Scale*
Global
Deterioration
Scale Stage General Features
1 No subjective symptoms or clinical evidence of memory deficit.
2 Subjective symptoms of memory deficit, such as forgetting the location of familiar objects or previously well-known
names.
3 Early, clear-cut memory deficits, such as getting lost, poor work performance, problems with word or name finding,
misplacing objects of value, or poor retention of written material.
4 Clear-cut memory deficits, such as poor knowledge of current events, difficulty remembering details of personal history,
impaired concentration doing serial subtractions, and inability to handle finances or travel to new places. Frequently,
there is no deficit in orientation to time and place, recognition of familiar faces, or travel to familiar locations.
5 Can no longer function without some assistance. Unable to recall major aspects of current life (e.g., address, telephone
number, names of family members). May need assistance dressing, but still independent in eating and toileting.
6 Occasionally forgets name of primary caregiver (e.g., spouse). Largely unaware of recent personal events. Substantial
assistance required with activities of daily living and travel to familiar locations. Often unaware of surroundings (e.g.,
year or season). Can still recall his or her own name and distinguish a familiar face.
7 Unable to recognize familiar faces, verbal abilities limited to <5 words, incontinent of urine and stool, total functional
dependence, and unable to walk.
*
Information is from reference 12.













Mitchell et al. Page 13
Table 2
Priorities for Advanced Dementia Research Over the Next Decade
Discipline Broad Research Objectives Specific Examples
Intervention Design and conduct RCTs of interventions to
promote high-quality, goal-directed care across
health care settings
Design and conduct RCTs of interventions to
reduce disparities in end-of-life care
RCT of an intervention to reduce hospital transfers for nursing
home residents with advanced dementia whose goal of care is
comfort
RCT of a clinical pathway to reduce feeding tube insertions in
hospitalized patients with advanced dementia
RCT of culturally sensitive video decision aids that use visual
images (vs. verbal explanations) to illustrate treatment options
Health policy/services Identify policies that incentivize high-quality, cost-
effective end-of-life care
Test strategies to increase access to hospice care
and palliative care programs
Conduct comparative effectiveness research of
treatment strategies
Develop and evaluate nursing home quality indicators for end-
of-life care
Examine effect of introducing payment for hospice during
receipt of skilled nursing facility care
Determine the incremental cost-effectiveness ratio of not
hospitalizing nursing home residents with advanced dementia
for suspected pneumonia (e.g., incremental changes in quality-
adjusted outcomes relative to costs)
Implementation Conduct projects to implement proven interventions
and policies
Demonstration project of evidence-based advanced dementia
care intervention into nursing home practice
Measurement Develop new advanced dementia-specific
instruments for outcomes currently lacking valid
measures
Better establish psychometric properties of existing
instruments
Measure of stress among family members of nursing home
residents with advanced dementia
Develop utility-based measures of health-related quality of life
in order to conduct comparative effective research
Determine minimally clinically important difference for
Symptom Management at the End-of-Life in Dementia Scale
(30)
RCT = randomized, controlled trial.
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